Market Newsdesk

November 18, 2020 1:24 pm

Tradeweb to Participate in Goldman Sachs 2020 U.S. Financial Services Conference

Tradeweb to Participate in Goldman Sachs 2020 U.S. Financial Services Conference

NEW YORK–(BUSINESS WIRE)–
Tradeweb Markets Inc. (Nasdaq: TW), a leading, global operator of electronic marketplaces for rates, credit, equities and money markets, today announced it will participate in the Goldman Sachs 2020 U.S. Financial Services Conference on Wednesday, December 9, 2020.

Tradeweb CEO Lee Olesky is scheduled to participate in a fireside chat at 2:00 PM EST on December 9. A live webcast and replay of the session will be available via http://investors.tradeweb.com for approximately 180 days following the conclusion of the event.

About Tradeweb Markets

Tradeweb Markets Inc. (Nasdaq: TW) is a leading, global operator of electronic marketplaces for rates, credit, equities and money markets. Founded in 1996, Tradeweb provides access to markets, data and analytics, electronic trading, straight-through-processing and reporting for more than 40 products to clients in the institutional, wholesale and retail markets. Advanced technologies developed by Tradeweb enhance price discovery, order execution and trade workflows while allowing for greater scale and helping to reduce risks in client trading operations. Tradeweb serves approximately 2,500 clients in more than 65 countries. On average, Tradeweb facilitated more than $780 billion in notional value traded per day over the past four fiscal quarters. For more information, please go to www.tradeweb.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005966/en/

Investor

Ashley Serrao, Tradeweb + 1 646 430 6027

[email protected]

Media

Daniel Noonan, Tradeweb +1 646 767 4677

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Data Management Technology Finance Software Banking

MEDIA:

November 18, 2020 1:18 pm

Data443 Announces Elimination of Warrants as Part of Settlment, Continues Path to Major Market Uplist

Shareholder Friendly Transaction Removes Significant Derivative Liability Component

RESEARCH TRIANGLE PARK, NC, Nov. 18, 2020 (GLOBE NEWSWIRE) — Data443 Risk Mitigation, Inc. (“Data443” or the “Company”) (OTCPK: ATDS), a leading data security and privacy software company for ALL THINGS DATA SECURITY™, is pleased to announce a settlement agreement with a long-term PIPE investor group resulting in elimination of substantial outstanding warrants.

MAJOR HIGHLIGHTS OF THE TRANSACTION:

Over 300,000,000 warrants have been cancelled
The Company has issued fixed-floor promissory notes to three investors in connection to the warrants with no derivative instruments attached for a total of $100,000
As a result, the Company has eliminated virtually all outstanding warrants and derivative liabilities outstanding pertaining to warrant conditions related to warrant-based instruments

Jason Remillard, CEO of Data443 commented, “This transaction is important for the Company’s continued financial health, removing a major hurdle towards completing further transactions that we are expecting to close in the near future. This transaction is an excellent resolution for the Company and introduces shareholder-friendly fixed debt instruments into our financing mix, that will continue to be important measures as we proceed into our next phases of our business growth. We thank our long-term investors for their continued support of the business and our joint goals!”

BUSINESS UPDATE CONFERENCE CALL

Data443 will hold a Business Update Conference Call and Webcast on Thursday, November 19, 2020 at 4:30pm ET.

Investors and other interested parties may submit their questions ahead of time by emailing Investor Relations at [email protected].

Online registration is available at: https://info.data443.com/2020q3-business-update

About Data443 Risk Mitigation, Inc.

Data443 Risk Mitigation, Inc. (OTCPK: ATDS), is the de facto industry leader in Data Privacy Solutions for All Things Data Security™, providing software and services to enable secure data across local devices, network, cloud, and databases, at rest and in flight. Its suite of products and services is highlighted by: (i) ARALOC^™, which is a market leading secure, cloud-based platform for the management, protection and distribution of digital content to the desktop and mobile devices, which protects an organization’s confidential content and intellectual property assets from leakage — malicious or accidental — without impacting collaboration between all stakeholders; (ii) DATAEXPRESS^®, the leading data transport, transformation and delivery product trusted by leading financial organizations worldwide; (iii) ArcMail^™, which is a leading provider of simple, secure and cost-effective email and enterprise archiving and management solutions; (iv) ClassiDocs^® the Company’s award-winning data classification and governance technology, which supports CCPA, LGPD, and GDPR compliance; (v) ClassiDocs^™ for Blockchain, which provides an active implementation for the Ripple XRP that protects blockchain transactions from inadvertent disclosure and data leaks; (vi) Data443^® Global Privacy Manager, the privacy compliance and consumer loss mitigation platform which is integrated with ClassiDocs^™ to do the delivery portions of GDPR and CCPA as well as process Data Privacy Access Requests – removal request – with inventory by ClassiDocs^™; (vii) Resilient Access™, which enables fine-grained access controls across myriad platforms at scale for internal client systems and commercial public cloud platforms like Salesforce, Box.Net, Google G Suite, Microsoft OneDrive and others; (viii) Data443^™ Chat History Scanner, which scans chat messages for Compliance, Security, PII, PI, PCI & custom keywords; (ix) the CCPA Framework WordPress plugin, which enables organizations of all sizes to comply with the CCPA privacy framework; (x) FileFacets™, a Software-as-a-Service (SaaS) platform that performs sophisticated data discovery and content search of structured and unstructured data within corporate networks, servers, content management systems, email, desktops and laptops; (xi) the GDPR Framework WordPress plugin, with over 30,000 active users and over 400,000 downloads it enables organizations of all sizes to comply with the GDPR and other privacy frameworks; and (xii) IntellyWP, a leading purveyor of user experience enhancement products for webmasters for the world’s largest content management platform, WordPress. For more information, please visit http://www.data443.com.

Forward-Looking Statements

The statements contained in this release that are not historical facts are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursuant,” “target,” “continue,” and similar expressions are intended to identify such forward-looking statements. The statements in this press release that are not historical statements, including statements regarding Data443’s plans, objectives, future opportunities for Data443’s services, future financial performance and operating results and any other statements regarding Data443’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts, are forward-looking statements within the meaning of the federal securities laws. These statements are not guarantees of future performance and are subject to numerous risks, uncertainties, and assumptions, many of which are beyond Data443’s control, and which could cause actual results to differ materially from the results expressed or implied by the statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, and include, without limitation, results of litigation, settlements and investigations; actions by third parties, including governmental agencies; volatility in customer spending; global economic conditions; ability to hire and retain personnel; loss of, or reduction in business with, key customers; difficulty with growth and integration of acquisitions; product liability; cybersecurity risk; anti-takeover measures in our charter documents; and, the uncertainties created by the ongoing outbreak of a respiratory illness caused by the 2019 novel coronavirus that was recently named by the World Health Organization as COVID-19. These and other important risk factors are described more fully in our reports and other documents filed with the Securities and Exchange Commission (“the SEC”), including under (i) “Part I, Item 1A. Risk Factors”, in our Registration Statement on Form 10 filed with the SEC on January 11, 2019 and amended on April 24, 2019; (ii) “Part I, Item 1A. Risk Factors”, in our Annual Report on Form 10-K filed with the SEC on 17 April 2020; and, (iii) subsequent filings. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Except as otherwise required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

The Data443^™ logo, ALL THINGS DATA SECURITY™, ClassiDocs^™ logo, ARALOC^™ logo and DATAEXPRESS^® are registered trademarks of Data443 Risk Mitigation, Inc.

All product names, trademarks and registered trademarks are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks and brands does not imply endorsement.

All other trademarks cited herein are the property of their respective owners.

For Further Information:

Follow us on Twitter: https://twitter.com/data443Risk
Follow us on Facebook: https://www.facebook.com/data443/
Follow us on LinkedIn: https://www.linkedin.com/company/data443-risk-mitigation-inc/
Signup for our Investor Newsletter: https://www.data443.com/investor-relations/

Investor Relations Contact:

Matthew Abenante
[email protected]
919.858.6542

November 18, 2020 1:16 pm

URAC Utilization Management Certifications FREE Webinar

URAC UM Certification

Washington, DC, Nov. 18, 2020 (GLOBE NEWSWIRE) — URAC is widely recognized by nearly every state and the federal government for health utilization management. Earning the URAC Health Utilization Management Accreditation seal is a mark of distinction for organizations that demonstrate their commitment to quality and accountability.

Our health utilization management standards are designed to ensure that organizations conducting utilization management follow a process that is clinically sound and respects patients’ and providers’ rights.

Join URAC as our industry leading experts share with you how our UM certifications can help you meet the highest quality standards in patient care management. This webinar will answer your questions about how your organization can reap the benefits of certification and put you in a better position to serve patients, providers, and most importantly, your clients.

This webinar will provide a brief overview of the four certifications and share some of the benefits of being a URAC-certified delegated HUM entity.

URAC Utilization Management Certifications

Thursday, December 3, 11:00am to 12:00pm (EST)

Thank you,

Laura Wood
Director Of Communications
URAC
E-mail: [email protected]

Attachment

ThinkstockPhotos-5329553491

Laura Wood, Director
URAC
202-326-3968
[email protected]

November 18, 2020 1:15 pm

European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older

European Commission approves Supemtek

^®

(quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older

First and only recombinant influenza vaccine approved in the European Union
Contains three times more antigen than standard-dose vaccines
Phase 3 efficacy trial demonstrated improved protection against influenza compared to standard-dose influenza vaccine, and reduced the risk of influenza by an additional 30% in adults aged 50 years and older^1,2

PARIS – November 18, 2020 – The European Commission has granted a marketing authorization for Supemtek^®, a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older. Supemtek is the first and only recombinant influenza vaccine now approved in the European Union.

Supemtek is produced using recombinant technology, which allows an exact match to the key component of the influenza strains recommended by the World Health Organization, avoiding the risk of viral mutations. Supemtek also contains three times more antigen than both egg-based and cell-based standard-dose vaccines. This increased amount of antigen and the use of recombinant technology provide improved protection against influenza, particularly in those aged 50 and older. In comparison with a standard-dose egg-based quadrivalent influenza vaccine, Supemtek reduced the risk of influenza by an additional 30% for adults aged 50 years and older^1,2.

The authorization is based on clinical data demonstrating safety, immunogenicity and efficacy of Supemtek in two Phase 3 randomized controlled trials¹^,² involving more than 10,000 patients in total. Specifically, the relative efficacy of Supemtek was demonstrated in a Phase 3 multicenter (40 outpatient centers in the US, involving more than 9,000 adults), randomized controlled efficacy trial^1,2.

“In the context of the COVID-19 pandemic, preventing influenza remains a public health priority,” said Thomas Triomphe, Head of Sanofi Pasteur. “Today’s approval of Supemtek supports our strong commitment in advancing influenza vaccine technology. With Supemtek, we provide European health authorities with an additional innovative solution that has demonstrated increased ability to prevent influenza and its potentially severe complications, as well as the burden this causes on healthcare systems.”

Each year, influenza-associated deaths range from 290,000 to 650,000³^,⁴ globally, and the burden on hospitals is around 10 million of influenza-related hospitalizations⁵. Recent data also show that influenza can multiply the risk of heart attack by up to 10 times, and the risk of stroke by up to 8 times, in the week after influenza infection⁶ – demonstrating that the burden of influenza goes beyond its well-known respiratory complications.

The first European launches are expected for the 2022/2023 influenza season, with a possibility of accelerating the availability of doses as early as the 2021/2022 season in certain countries. Outside of the EU, Supemtek is also approved in the U.S. under the tradename Flublok Quadrivalent^®.

About the recombinant technology

The recombinant technology is a new way of producing influenza vaccines which differs significantly from the two other technologies currently in use (egg-based and cell-based technologies) as it avoids the risk of viral mutations that can lower vaccine efficacy. It ensures the exact match to the key component of the influenza strains recommended by the World Health Organization every year for producing influenza vaccines.

In an independent systematic review⁷ published in October 2020, the European Center for Disease Prevention notes that “the recombinant haemagglutinin was found to provide a greater protective effect against overall influenza compared with no vaccination and with traditional influenza vaccination […] this effect may be attributable to either the restriction of mutations seen with egg-based vaccines or the higher dose of antigen seen in this type of influenza vaccine”.

The recombinant technology is also used for the development of one of Sanofi’s vaccines against COVID-19, developed in partnership with GSK and with the support of US Biomedical Advanced Research and Development Authority (BARDA). The Companies announced the start of the Phase 1/2 clinical trial for their adjuvanted recombinant COVID-19 vaccine candidate in September and anticipate first results in December 2020, to support the initiation of a pivotal Phase 3 study before the end of the year. If these data are sufficient for licensure application, Sanofi and GSK plan to request regulatory approval in the first half of 2021.

Increased production of seasonal influenza vaccines in the unique context of the COVID-19 pandemic

As the leading manufacturer of influenza vaccines, Sanofi Pasteur, the vaccines global business unit of Sanofi, is supporting health authorities in their efforts to strengthen influenza vaccination campaigns in the unique context of COVID-19. For the 2020/2021 influenza season, the Company is delivering globally 20% more doses of flu vaccines, reaching an unprecedented production level of 250 million doses, across its influenza vaccine portfolio which includes a wide range of vaccines (standard doses and differentiated vaccines) that are proven to protect people of all ages from the risks of influenza.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Media Relations Contact

Nicolas Kressmann
Tel.: +1 (732) 532-5318
[email protected]

Investor Relations Contacts Paris
Eva Schaefer-Jansen
Arnaud Delepine
Yvonne Naughton

Investor Relations Contacts North America
Felix Lauscher
Fara Berkowitz
Suzanne Greco

IR main line:
Tel.: +33 (0)1 53 77 45 45
[email protected]

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

¹

Dunkle LM, Izikson R, Patriarca P, et al. 2017

²

Dunkle LM, Izikson R, et al. 2017a

³

Centers for Disease Control and Prevention. Flu symptoms and complications

⁴

WHO factsheet

⁵
Lancet Respir Med 2019; 7: 69–89

⁶
Warren-Gash C, et al. Eur Respir J. 2018:51

⁷

Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines. ECDC. Oct 2020

Attachment

November 18, 2020 1:14 pm

ROSEN, A LONGSTANDING AND TRUSTED LAW FIRM, Reminds First American Financial Corp. Investors of Important Deadline in Securities Class Action First Filed by the Firm – FAF

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of First American Financial Corp. (NYSE: FAF) between February 17, 2017 and October 22, 2020, inclusive (the “Class Period”), of the important December 24, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for First American investors under the federal securities laws.

To join the First American class action, go to http://www.rosenlegal.com/cases-register-1662.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) First American failed to implement basic security standards to protect its customers’ sensitive personal information and data; (2) First American faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 24, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1662.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40^th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com

November 18, 2020 1:10 pm

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action – ZSAN

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”), of the important December 28, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Zosano investors under the federal securities laws.

To join the Zosano class action, go to ht t p://www.rosenlegal.com/cases-register-1963.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company’s New Drug Application (“NDA”) included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require further studies to support regulatory approval of Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 28, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1963.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com

November 18, 2020 1:08 pm

Remark Holdings Adjourns Special Shareholder Meeting Until December 16, 2020

PR Newswire

LAS VEGAS, Nov. 18, 2020 /PRNewswire/ — Remark Holdings, Inc. (NASDAQ: MARK), a diversified global technology company with leading artificial intelligence (“AI”) solutions and digital media properties, today announced the adjournment of its special shareholder meeting until December 16, 2020 at 1:00 p.m. ET, to provide additional time to solicit votes to reach a quorum and conduct business.

About Remark Holdings, Inc.

Remark Holdings, Inc. (NASDAQ: MARK) delivers an integrated suite of AI solutions that enable businesses and organizations to solve problems, reduce risk and deliver positive outcomes. The company’s easy-to-install AI products are being rolled out in a wide range of applications within the retail, public safety and workplace arenas. The company also owns and operates an e-commerce digital media property focused on a luxury beach lifestyle. The company is headquartered in Las Vegas, Nevada, with additional operations in Los Angeles, California and in Beijing, Shanghai, Chengdu and Hangzhou, China. For more information, please visit the company’s website at www.remarkholdings.com.

Forward-Looking Statements

This press release may contain forward-looking statements, including information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, including those discussed in Part I, Item 1A. Risk Factors in Remark Holdings’ Annual Report on Form 10-K and Remark Holdings’ other filings with the SEC. Any forward-looking statements reflect Remark Holdings’ current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given such uncertainties, you should not place undue reliance on any forward-looking statements, which represent Remark Holdings’ estimates and assumptions only as of the date hereof. Except as required by law, Remark Holdings undertakes no obligation to update or revise publicly any forward-looking statements after the date hereof, whether as a result of new information, future events or otherwise.

Company Contacts

E. Brian Harvey
Senior Vice President of Capital Markets and Investor Relations
Remark Holdings, Inc.
[email protected]
702-701-9514

Fay Tian

Vice President of Investor Relations
[email protected]
(+1) 626-623-2000
(+86) 12702108000

View original content to download multimedia:http://www.prnewswire.com/news-releases/remark-holdings-adjourns-special-shareholder-meeting-until-december-16-2020-301176274.html

SOURCE Remark Holdings, Inc.

November 18, 2020 1:07 pm

Instaclustr Named to Deloitte’s 2020 Technology Fast 500™ as Enterprises Increasingly Turn to Open Source for Their Data Stacks

Providing integrated and fully managed open source data-layer solutions to a global customer base, Instaclustr earns the recognition following three-year revenue growth of 389%

REDWOOD CITY, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) — Instaclustr, delivering reliability at scale through fully managed open source data technologies, today announced it ranked 283 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 26^th year. Instaclustr grew 389% during this period.

Instaclustr’s accelerated growth is a testament to the transformational power of the modern and enterprise-ready open source data-layer solutions the company delivers to customers across industries. Businesses turn to Instaclustr to unlock the strategic and architecture advantages of proven open source data technologies with the most scalable, versatile, and high-performance capabilities. The solutions Instaclustr provides are designed to eliminate the cost inefficiencies and operational burdens of running these solutions internally; Instaclustr actively manages and optimizes the data layer to allow customers to focus resources on developing their products and growing their businesses.

Instaclustr continues to expand its open source data-layer ecosystem, most recently with the addition of managed Redis. The popular open source in-memory database joins managed Apache Cassandra, Apache Kafka, Kafka Connect, and Elasticsearch as part of Instaclustr’s complete data-layer platform built for deploying and scaling mission-critical applications. Instaclustr is committed to delivering all solutions in their 100% open source versions. This frees customers from the risks of vendor and technical lock-in inherent to “open core” offerings, which also drive up costs and reduce application portability.

“Getting the data layer right has never been more critical,” said Peter Lilley, CEO, Instaclustr. “We believe that continually achieving the scale, performance, security, and reliability goals of the modern enterprise hinges on the right data technologies guided by the right expertise. We’ve seen a tremendous pace of growth as a one-stop destination for deploying, managing, and monitoring all components of customers’ data layer – and open source is a big component ensuring enterprises can get there without compromising on flexibility or budget. We’re deeply honored to be included in the Deloitte Technology Fast 500, and look forward to continuing to expand the services, support, and technologies that we offer our customers.”

“For more than 25 years, we’ve been honoring companies that define the cutting edge and this year’s Technology Fast 500 list is proof positive that technology — from software and digital media platforms, to biotech — truly does permeate so many facets of our lives,” said Paul Silverglate, vice chairman, Deloitte LLP and U.S. technology sector leader. “We congratulate this year’s winners, especially during a time when innovation is needed more than ever to address the monumental challenges posed by the pandemic.”

“Each year the Technology Fast 500 listing validates how important technology innovation is to our daily lives. It was interesting to see this year that while software companies continued to dominate, biotech companies rose to the top of the winners list for the first time, demonstrating that new categories of innovation are accelerating in the pursuit of making life easier, safer and more productive,” said Mohana Dissanayake, partner, Deloitte & Touche LLP, and industry leader for technology, media and telecommunications, within Deloitte’s audit and assurance practice. “We extend sincere congratulations to these well-deserved winners — who all embody a spirit of curiosity, and a never-ending commitment to making technology advancements possible.”

For additional details on the Technology Fast 500, including the complete list and qualifying criteria, visit www.fast500.com.

About Instaclustr

Instaclustr
delivers reliability at scale through our integrated data platform of open source technologies such as Apache Cassandra®, Apache Kafka®, Apache Spark™, Redis™ and Elasticsearch. We enable companies to focus internal development and operational resources on building cutting edge customer-facing applications. Instaclustr now has more than 70 million node hours and 7 PB of data under management across its open source technology suite.

For more information, visit Instaclustr.com and follow us @Instaclustr.

About Deloitte’s
2020
Technology Fast 500™

Now in its 26^th year, Deloitte’s Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2016 to 2019.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $US50,000, and current-year operating revenues of at least $US5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Instaclustr Contact
Kyle Peterson
[email protected]

November 18, 2020 1:04 pm

Foot Locker Launches ’12 Days of Greatness’ Holiday Campaign Featuring Exclusive Basketball-Inspired Capsule Collections

‘The Worst Kept Secret’ unintentionally unveiled in tandem with one of basketball’s biggest nights

PR Newswire

NEW YORK, Nov. 18, 2020 /PRNewswire/ — This year, Foot Locker is launching the “12 Days of Greatness,” a unique basketball-inspired holiday collection celebrating universal love of the game. To bring 12 Days of Greatness to life, Foot Locker has teamed up with some of the best streetwear designers in and around basketball culture.

With much anticipation, Foot Locker kept its 12 Days of Greatness capsule collections under wraps as long as possible, but “The Worst Kept Secret” was blown today when designer Don C gifted four draft hopefuls – Cole Anthony, Anthony Edwards, Onyeka Okongwu and James Wiseman – with early access to Foot Locker exclusive apparel to wear on their big night.

Collaborating with some of the biggest names in streetwear, sneaker and basketball culture – including Waraire Boswell, Don C, Melody Ehsani, Montrezl Harrell, Kyle Kuzma, Sami Miro, PJ Tucker and Rhuigi Villaseñor – presents a unique set of challenges, as their products and collaborations are highly coveted. “The Worst Kept Secret,” directed by Director X, illustrates the great lengths the designers went through to keep 12 Days of Greatness a covert project.

“This year we’ve re-imagined our holiday shopping experience to not only release the hottest footwear but offer our community unique apparel and accessories that speak to their interests in all things basketball and sneaker culture,” said Richard McLeod, Vice President of Marketing for Foot Locker, North America. “12 Days of Greatness is an opportunity for us to celebrate our collective love of basketball and the culture that surrounds the game.”

Each capsule collection will drop on one of 12 Days between Nov. 20 and Dec. 26. Featured designers include:

Rhude x Starter	Melody Ehsani	Just Don
Chinatown Market	PJ Tucker x Joe Perez	Waraire Boswell
And 1 x Jeff Cole	Sami Miro	Starter x Ty Mopkins
BE@RBRICK	Andrea Bergart	Vainglory
Jeff Staple	Perico Limited	Trophy Hunting
Distortedd	Kool Kiy	Live Life Nice
LA Originals	Viva La Bonita	SlauCienega
Montrezl Harrell x Reebok	Kyle Kuzma x Rhude x PUMA	Kid Cudi x adidas
adidas Originals x Chelsea Gray, Nneka Ogwumike and Candace Parker

In addition to Foot Locker’s exclusive apparel and accessories, 12 Days of Greatness will also feature a curated assortment of the season’s hottest footwear releases from Nike, Jordan, adidas, PUMA, Reebok, New Balance and more. Visit Foot Locker’s Release Calendar for drop dates and release procedures, and regularly check www.footlocker.com/12daysofgreatness, as more secret details and specifics of the 12 Days will be revealed soon.

Foot Locker’s Worst Kept Secret campaign was created by worldwide agency BBDO New York. Join the conversation by visiting @footlocker @footlockerwomen and @kidsfootlocker on Twitter, Instagram and Facebook, using #12DaysofGreatness.

About Foot Locker

:

Foot Locker, Inc. leads the celebration of sneaker and youth culture around the globe through a portfolio of brands including Foot Locker, Lady Foot Locker, Kids Foot Locker, Champs Sports, Eastbay, Footaction, and Sidestep. With approximately 3,100 retail stores in 27 countries across North America, Europe, Asia, Australia and New Zealand, as well as websites and mobile apps, the Company’s purpose is to inspire and empower youth around the world, by fueling a shared passion for self-expression and creating unrivaled experiences at the heart of the global sneaker community. Foot Locker, Inc. has its corporate headquarters in New York.

Additional information may be found at footlocker.com | Twitter: @footlocker | Instagram: @footlocker | YouTube: youtube.com/footlocker | Facebook: facebook.com/footlocker

View original content to download multimedia:http://www.prnewswire.com/news-releases/foot-locker-launches-12-days-of-greatness-holiday-campaign-featuring-exclusive-basketball-inspired-capsule-collections-301176164.html

SOURCE Foot Locker, Inc.

November 18, 2020 1:03 pm

MTS Announces 2020 Second quarter Financial Results

PR Newswire

POWDER SPRINGS, Ga. and RA’ANANA, Israel, Nov. 18, 2020 /PRNewswire/ — Mer Telemanagement Solutions Ltd. (MTS) (Nasdaq Capital Market: MTSL), a global provider of telecommunications expense management (TEM), call accounting and contact centre software, today released its financial results for the three and six months ended June 30, 2020.

The Company recorded revenues of $948,000 for the three months ended June 30, 2020, compared with $1,317,000 for the three months ended June 30, 2019. Net loss from continuing operation, including one-time non-cash impairment charges of $617,000, amounted to $628,000 or $0.11 per diluted share for the three months ended June 30, 2020 compared with a net loss from continuing operation of $76,000, or $0.02 per diluted share, for the comparable period in 2019. On a non-GAAP basis (as described and reconciled below), the Company incurred a net loss of $4,000 or $0.00 per diluted share, for the three months ended June 30, 2020 compared with a net loss of $65,000, or $0.01 per diluted share, for the comparable period in 2019.

The Company recorded revenues of $2.1 million for the six months ended June 30, 2020 compared with $2.6 million for the comparable period in 2019. Net loss from continuing operation, including one-time, non-cash impairment charges of $617,000 amounted to $660,000, or $0.12 per diluted share, for the six months ended June 30, 2020 compared with a net loss from continuing operation of $206,000, or $0.04 per diluted share for the comparable period in 2019. On a non-GAAP basis (as described and reconciled below), the Company posted a net loss of $29,000, or $0.01 per diluted share for the six months ended June 30, 2020compared with a net loss of $183,000, or $0.03 per diluted share for the comparable period in 2019.

During 2018 an institutional investor invested, $1.5 million in a newly-created class of convertible preferred shares and $0.2 million in ordinary shares of the Company. During 2020 and 2019, the institutional investor partially exercised its greenshoe option and purchased additional $1.5 million of the convertible preferred shares, which are convertible into ordinary shares on a one for one basis.

Commenting on the results, Mr. Roy Hess, Chief Executive Officer of MTS, said, “Our results in 2020 reflect the efficiency plan we implemented during 2019 in order to adjust our operating expenses attributable to the declining sales and to improve our operating margins. Excluding the impact of the one-time non-cash impairment charges, our net loss for the quarter was $4,000 on a non-GAAP basis In June 2019, we introduced Omnis – Contact Center Software with “Out-Of-The-Box” capabilities and open channel architecture. We have begun to see initial revenues from this new product, whose introduction has been hampered by the constraints arising from the spread of COVID-19. As previously reported, we are also continuing our efforts to find a suitable M&A candidate for our company which will enhance shareholder value.”

About MTS

Mer Telemanagement Solutions Ltd. (MTS) is focused on innovative products and services for enterprises in the area of telecom expense management (TEM), call accounting and contact center software. Headquartered in Israel, MTS markets its solutions through wholly-owned subsidiaries in Israel, the U.S and Hong Kong, as well as through distribution channels. For more information please visit the MTS web site: www.mtsint.com.

Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, the Company’s ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ continued listing requirements, customer acceptance of new products, the impact of competitive products and pricing, market acceptance, the lengthy sales cycle, proprietary rights of the Company and its competitors, risk of operations in Israel, general economic conditions and other risk factors detailed in the Company’s annual report and other filings with the United States Securities and Exchange Commission.

Contacts:

Ofira Bar
CFO
Tel: +972-9-7777-540
Email: [email protected]


CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands

	June 30,		December, 31
	2020	2019
	(Unaudited)	(Audited)
ASSETS

CURRENT ASSETS:
Cash and cash equivalents	$ 2,210	$ 1,732
Restricted cash	431	1,464
Trade receivables	414	499
Other accounts receivable and prepaid expenses	221	236
Assets of discontinued operations	178	172

Total current assets	3,454	4,103

SEVERANCE PAY FUND	350	653

PROPERTY AND EQUIPMENT, NET	49	62

GOODWILL	2,608	3,225

Total assets	$ 6,461	$ 8,043

CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share and per share data)

	June 30,	December 31,
	2020	2019
	(Unaudited)	(Audited)

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES:
Trade payables	$ 110	$ 149
Deferred revenues	1,020	962
Accrued expenses and other liabilities	1,202	2,317
Liabilities of discontinued operations	488	516

Total current liabilities	2,820	3,944

LONG-TERM LIABILITIES:
Accrued severance pay	417	831
Deferred tax liability	55	163

Total long-term liabilities	472	994

COMMITMENTS AND CONTINGENT LIABILITIES

SHAREHOLDERS’ EQUITY:
Share capital –
Ordinary shares	37	30
Preferred Shares	15	16
Additional paid-in capital	31,354	30,635
Treasury shares at cost	(29)	(29)
Accumulated deficit	(28,208)	(27,547)

Total shareholders’ equity	3,169	3,105

Total liabilities and shareholders’ equity	$ 6,461	$ 8,043

CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share and per share data)

	Six months ended		Three months ended
	June 30,		June 30,
	2020	2019	2020	2019
	Unaudited
Revenues:
Services	$ 1,815	$ 2,258	$ 913	$ 1,120
Product sales	288	342	35	197

Total revenues	2,103	2,600	948	1,317

Cost of revenues:
Services	693	785	321	393
Product sales	173	196	80	98

Total cost of revenues	866	981	401	491

Gross profit	1,237	1,619	547	826

Operating expenses:
Research and development	–	268	–	135
Selling and marketing	459	553	194	267
General and administrative	937	978	482	484
Goodwill impairment	617	–	617	–

Total operating expenses	2,013	1,799	1,293	886

Operating loss	(776)	(180)	(746)	(60)
Financial income (expenses), net	8	(25)	10	(15)

Loss before taxes on income	(768)	(205)	(736)	(75)
Taxes on income (tax benefit), net	(108)	1	(108)	1

Net loss from continuing operations	(660)	(206)	(628)	(76)
Loss from discontinued operations	(1)	(14)	(13)	(16)
Net loss	$ (661)	$ (220)	$ (641)	$ (92)

Net loss per share:
Basic and diluted net loss per share from continuing operations	$ (0.12)	$ (0.04)	$ (0.11)	$ ( 0.02)
Basic and diluted net loss per share from discontinued operations	(0.00)	(0.00)	(0.00)	( 0.00)
Basic and dilutednet loss per share	$ (0.12)	$ (0.04)	$ ( 0.11)	$ ( 0.02)
Weighted average number of shares used in computing basic and diluted net loss per share	5,645,400	4,698,440	5,669,621	4,783,115

RECONCILIATION OF GAAP TO NON-GAAP RESULTS
U.S. dollars in thousands (except share and per share data)

	Six months ended June 30,		Three months ended June 30,
	2020	2019	2020	2019
		Unaudited

GAAP net loss from continuing operations	(660)	(206)	(628)	(76)
Stock-based compensation expenses	14	13	7	6
Intangible assets amortization, net of tax effects	–	10	–	5
Goodwill impairment, net of tax effect	617	–	617	–

Non-GAAP net loss	$ (29)	$ ( 183)	$ (4)	$ ( 65)

Net loss per share:

GAAP basic and diluted net loss per share	$ (0.12)	$ (0.04)	$ (0.11)	$ (0.02)
Non-GAAP basic and diluted net loss per share	$ (0.01)	$ (0.03)	$ (0.00)	$ (0.01)

Weighted average number of shares used in computing non-GAAP basic and diluted net loss per share	5,645,400	4,698,440	5,669,621	4,783,115

Logo – https://mma.prnewswire.com/media/777768/MTS_Logo.jpg

View original content:http://www.prnewswire.com/news-releases/mts-announces-2020-second-quarter-financial-results-301176282.html

SOURCE Mer Telemanagement Solutions Ltd. (MTS)